Abstract
Multiple therapeutic modalities have been used to treat hepatic encephalopathy. l-Acetylcarnitine (LAC) is a physiologically active substance that improves both the energetic and the neurotransmission profiles. LAC is able to cross the hematoencephalic barrier and reach the cerebral regions, where the acetylic group may be utilized. The aim of this work was to evaluate the efficacy of LAC in the treatment of hepatic coma in cirrhotic patients. Twenty-four suitably selected patients were enrolled in the study and, following randomization, received either LAC (n=13) or placebo (n=11). Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment. In the placebo group we observed two cases of improved neurological findings as well as one case of improved EEG grading. In the other group we observed an improvement of neurological findings and of EEG grade in 10 and 8 subjects, respectively. Noteworthily, seven (54%) patients went from grade 4 down to grade 3, and one from grade 4 down to grade 1. The improvement in the neurological picture was evident at between 1 and 4 hr after the end of treatment, remaining until 24 hr after. No side effects were observed in our study series. Our study demonstrates that LAC administration improved neurological and biohumoral symptoms in selective cirrhotic patients with hepatic coma.
Similar content being viewed by others
References
Jones EA, Weissenborn K (1997) Neurology and the liver. JNNP 63:279–293
Blei AT (2000) Diagnosis and treatment of hepatic encephalopathy. Baillieres Best Pract Res Clin Gastroenterol 14:959–974
Licinio J, Wong ML (1997) Pathways and mechanisms for cytokine signalling of the central nervous system. J Clin Invest 100:2941–2947
Yurdaycin C, Walsh TJ, Engler HD, Ha JH, Li Y, Jones EA, Basile AS (1995) Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 679:42–48
Zieve L, Onstad GR (1980) High brain concentration of phenylalanine, tryptophan and methionine do not cause coma in rats or dogs. Gastroenterology 79:1070
Norenberg MD (1996) Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 16:245–253
Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF (1998) Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet 35:719–721
Malaguarnera M, Trovato BA, Pistone G, Scuderi M, Vinci M, Romano M, Marletta F (1996) Electrophysiological alterations in hepatic encephalopathy detected by brain mapping. Panminerva Med 38:84–88
Haussinger D, Kircheis G, Fischer R, Schliess F, von Dahl S (2000) Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 32:1035–1038
Basile AS, Jones EA (1997) Ammonia and GABAergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 25:103–105
Farrel L, Vogel J, Bierber LL (1986) Entry of L-acetylcarnitine into biosynthetic pathways. Biochim Biophys Acta 876:175–177
Siliprandi N, Siliprandi D, Ciman M (1965) Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. Biochem J 96:777–780
Montgomery SA, Thal LJ, Amrein R (2003) Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18:61–71
Virmani A, Binienda Z (2004) Role of carnitine esters in brain neuropathology. Mol Aspects Med 25:533–549
Conn HO, Lieberthal MM (1979) The hepatic coma syndromes and lactulose. Williams and Wilkins, Baltimore, pp 1–121
Pappas SC, Jones EA (1983) Methods for assessing hepatic encephalopathy. Semin Liver Dis 3:298–307
Tesdale G, Jennet B (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 2:81–83
De Fonseca-Wollheim F (1973) Direkte plasmaammoniakbestimmung ohne Enteiweissung. Clin Chem Clin Biochem 11:421–431
Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328:1046
Plauth M, Raible A, Graser TA, Noldeke IL, Furst P, Dolle W, Hartmann F (1994) Lactulose or paromomycin do not affect ammonia generation in the isolated perfused rat small intestine. Z Gastroenterol 32:141–145
Goulenok C, Bernard B, Cadranel JF, Thabut D, Di Martino V, Opolon P, Poynard T (2002) Flumazenil vs placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 16:361–372
Scollo Lavizzari G, Steinmann E (1985) Reversal of hepatic coma by benzodiazepine antagonist (RO 15-1788). Lancet 1:1324
Bansky G, Meier PJ, Ziegler WH, Walser H, Schmidt M, Huber M (1985) Reversal of hepatic coma by benzodiazepine antagonist (RO15-1788). Lancet 1:1324–1325
Pomier-Layrargues G, Giguere JF, Lavoice J, et al. (1994) Flumazenil in cirrhotic patients in hepatic coma: a randomised double blind placebo-controlled crossover trial. Hepatology 19:32–37
Gyr K, Meier R, Haussler J, et al. (1996) Evaluation of efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: double-blind, randomised, placebo-controlled multicentre study. Gut 39:319–324
Clouet P, Sempore G, Tsoko M, Gresti J, Demarquoy J, Niot I, Bezard J, Martin-Privat P (1996) Effect of short- and long-term treatments by a low level of dietary L-carnitine on parameters related to fatty acid oxidation in Wistar rat. Biochim Biophys Acta 1299:191–197
Ahern DA, Mitchell ME (1989) Liver function in protein-energy malnutrition measured by cinnamic acid tolerance and benzoic acid tolerance: effect of carnitine supplementation. Br J Nutr 61:209–221
Therrien G, Rose C, Butterworth J, Butterworth RF (1997) Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portocaval shunted rat. Hepatology 25:551–556
O’Connor JE, Costell M, Grisolia S (1984) Prevention of ammonia toxicity by L-carnitine: metabolic changes in brain. Neurochem Res 9:563–570
Malaguarnera M, Pistone G, Astuto M, Dell’Arte S, Finocchiaro G, Lo Giudice E, Pennisi G (2003) L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 21:271–275
Malaguarnera M, Pistone G, Rampello E, Leotta C, Scarpello L, Rampello L (2005) Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11:7197–7202
McCandless DW, Schenker S (1981) Effect of acute ammonia intoxication on energy stores in the cerebral reticular activating system. J Neurochem 44:325–330
Cooper AJL, Mora SN, Cruz NF, Gelbard AS (1985) Cerebral ammonia metabolism in hyperammonemic rats. J Neurochem 44:1716–1723
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malaguarnera, M., Pistone, G., Astuto, M. et al. Effects of l-Acetylcarnitine on Cirrhotic Patients with Hepatic Coma: Randomized Double-Blind, Placebo-Controlled Trial. Dig Dis Sci 51, 2242–2247 (2006). https://doi.org/10.1007/s10620-006-9187-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9187-0